Zoetis Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 14,500

Employees

  • Stock Symbol
  • ZTS

Stock Symbol

  • Investments
  • 34

  • Share Price
  • $79.11
  • (As of Friday Closing)

Zoetis General Information

Description

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 30% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 70% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Contact Information

Website
www.zoetis.com
Formerly Known As
Pfizer Animal Health
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 10 Sylvan Way
  • Parsippany, NJ 07054
  • United States
+1 (973)
Primary Industry
Other Agriculture
Other Industries
Other Commercial Products
Stock Exchange
NYS
Corporate Office
  • 10 Sylvan Way
  • Parsippany, NJ 07054
  • United States
+1 (973)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zoetis Stock Performance

As of 20-Nov-2026, Zoetis’s stock price is $79.11. Its current market cap is $32.1B with 406M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$79.11 $80.79 $68.77 - $132.49 $32.1B 406M 4.51M $5.89

Zoetis Financials Summary

As of 30-Sep-2026, Zoetis has a trailing 12-month revenue of $9.5B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 36,420,404 60,641,020 78,553,315 95,605,269
Revenue 9,494,000 9,467,000 9,256,000 8,544,000
EBITDA 3,755,000 3,976,000 3,749,000 3,563,000
Net Income 2,507,000 2,673,000 2,486,000 2,344,000
Total Assets 15,088,000 15,467,000 14,237,000 14,286,000
Total Debt 9,237,000 9,238,000 6,744,000 6,755,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Zoetis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Zoetis‘s full profile, request access.

Request a free trial

Zoetis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earn
Other Agriculture
Parsippany, NJ
14,500 As of 2025

Indianapolis, IN
 

Lansing, MI
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Zoetis Competitors (5)

One of Zoetis’s 5 competitors is Elanco Animal Health, a Corporation company based in Indianapolis, IN.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Elanco Animal Health Corporation Indianapolis, IN
Neogen (Lansing) Formerly VC-backed Lansing, MI
Phibro Animal Health Formerly PE-Backed Teaneck, NJ
Vetoquinol Formerly PE-Backed Lure, France
Idexx Laboratories Formerly VC-backed Westbrook, ME
You’re viewing 5 of 5 competitors. Get the full list »

Zoetis Patents

Zoetis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026217876-A1 Compositions and methods for enhancing the stability of a canine antibody Pending 11-Apr-2025
WO-2026136402-A1 Compositions and methods for improving canine antibody functions Pending 19-Dec-2024
WO-2026136223-A1 Compositions and methods for improving feline antibody functions Pending 19-Dec-2024
WO-2026122475-A1 Dna vaccine against infectious salmon anemia virus Pending 04-Dec-2024
WO-2026106884-A1 Process for preparing immunogenic azalides Pending 12-Nov-2024 C07H17/08
To view Zoetis’s complete patent history, request access »

Zoetis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zoetis Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Zoetis‘s full profile, request access.

Request a free trial

Zoetis Investments & Acquisitions (34)

Zoetis’s most recent deal was a Merger/Acquisition with VitalRads. The deal was made on 31-Jul-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
VitalRads 31-Jul-2026 Merger/Acquisition Other Services (B2C Non-Financial)
Techcyte 30-Apr-2026 Later Stage VC Decision/Risk Analysis
GeneSeek 02-Mar-2026 Merger/Acquisition Biotechnology
Veterinary Pathology Group 10-Nov-2025 Merger/Acquisition Other Services (B2C Non-Financial)
Espuña (45,000 Square Meters Parcel of Land in La Vall de Bianya, Spain) 01-Mar-2024 Corporate Asset Purchase Buildings and Property
You’re viewing 5 of 34 investments and acquisitions. Get the full list »

Zoetis ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

13.77 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Zoetis’s complete esg history, request access »

Zoetis Exits (2)

Zoetis’s most recent exit was on 08-Apr-2020 from Performance Livestock Analytics. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Performance Livestock Analytics 08-Apr-2020 Completed
KL Products 06-Aug-2015 Merger/Acquisition Completed
To view Zoetis’s complete exits history, request access »

Zoetis Affiliates

Subsidiaries (9)

Name Industry Location Year Founded
PetMedix Cambridge, United Kingdom 2017
Basepaws Kalamazoo, MI 2016
NewMetrica Glasgow, United Kingdom 2013
Virtual Recall Leatherhead, United Kingdom 2011
Veterinary Pathology Group Exeter, United Kingdom 2001
You’re viewing 5 of 9 affiliates. Get the full list.  »

Zoetis FAQs

  • When was Zoetis founded?

    Zoetis was founded in 2012.

  • Where is Zoetis headquartered?

    Zoetis is headquartered in Parsippany, NJ.

  • What is the size of Zoetis?

    Zoetis has 14,500 total employees.

  • What industry is Zoetis in?

    Zoetis’s primary industry is Other Agriculture.

  • Is Zoetis a private or public company?

    Zoetis is a Public company.

  • What is Zoetis’s stock symbol?

    The ticker symbol for Zoetis is ZTS.

  • What is the current stock price of Zoetis?

    As of 20-Nov-2026 the stock price of Zoetis is $79.11.

  • What is the current market cap of Zoetis?

    The current market capitalization of Zoetis is $32.1B.

  • What is Zoetis’s current revenue?

    The trailing twelve month revenue for Zoetis is $9.5B.

  • Who are Zoetis’s competitors?

    Elanco Animal Health, Neogen (Lansing), Phibro Animal Health, Vetoquinol, and Idexx Laboratories are competitors of Zoetis.

  • What is Zoetis’s annual earnings per share (EPS)?

    Zoetis’s EPS for 12 months was $5.89.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process